The RMAT designation is intended to expedite the development and evaluation of regenerative medicine therapies.

About 1 million Americans suffer from Parkinson's disease, with around 90,000 new cases diagnosed each year, according to the Parkinson's Foundation. The chronic, degenerative brain disorder destroys ...

FDA fast-tracks novel Parkinson’s cell therapy NouvNeu001, advancing treatment for dopaminergic neuron loss and motor ...

Researchers have identified a key molecular interaction that accelerates Parkinson’s disease by damaging the brain’s energy ...

Scientists have identified the role of an ion channel that plays a key part in how cells break down and recycle components, a discovery that could open the door to new treatment strategies for ...

A new initiative is set to explore the potential of repurposing existing medications to combat the symptoms of both Alzheimer’s and Parkinson’s diseases, aiming to accelerate the discovery of novel ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

In the late 1960s, scientists discovered a miracle drug for Parkinson’s disease — a simple, inexpensive dopamine-replacement pill called levodopa. It transformed the lives of millions of people.

In people with Parkinson's disease, dysphagia is usually treated first with medicines that aim to improve the symptoms of Parkinson’s disease overall. If swallowing problems continue, rehabilitation ...

A man expressing sadness with his head in his hands. Image by Tellmeimok. (CC BY-SA 4.0) A man expressing sadness with his head in his hands. Image by Tellmeimok. (CC BY-SA 4.0) A drug used for ...